Reviews
Vol. 8 No. 3 (2014)
https://doi.org/10.4081/itjm.2013.423

How to select appropriate hemoglobin target levels on health-related quality of life and outcomes for patients with chronic kidney disease?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 2 August 2013
Published: 2 December 2013
1621
Views
1393
Downloads
419
HTML
erythropoietin, erythropoiesis stimulating agents.
Internal Medicine Nephrology

Authors

Filippo Salvati
filippo.salvati@infinito.it
Department of Internal Medicine, Renzetti Hospital, Lanciano (CH), Italy.
According to the European guidelines and the American Kidney Disease Improving Global Outcomes (KDIGO) guidelines, in dialysis patients with chronic kidney disease (CKD), treatment target hemoglobin (Hb) values should be 11-12 g/dL without exceeding 13 g/dL. Doses of erythropoiesis-stimulating agent therapy should be considered to achieve the target hemoglobin level. Caution is recommended in diabetic CKD patients who do not require dialysis. In patients with ischemic heart disease or a previous history of stroke, possible benefits should be assessed against an increased risk of stroke recurrence, when selecting the Hb level.

Downloads

Download data is not yet available.

Supporting Agencies

no

How to Cite



How to select appropriate hemoglobin target levels on health-related quality of life and outcomes for patients with chronic kidney disease? (2013). Italian Journal of Medicine, 8(3), 158-160. https://doi.org/10.4081/itjm.2013.423

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.